Pharmaceuticals News and Research

RSS

Orexigen Therapeutics reports net loss of $18.6 million in Q3 2013

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced business and financial results for the third quarter ended September 30, 2013.

12 Nov 2013

Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has filed an investigational new drug application with the US Food and Drug Administration to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease.

12 Nov 2013

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their innovative ghrelin receptor agonist, anamorelin, for the three major European pharma markets.

12 Nov 2013

Avedro initiates US clinical trials for Lasik with cross-linking and pulsed accelerated cross-linking

Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company, announces today that the first patients have been treated in two new US clinical trials: Lasik with Cross-linking and Pulsed Accelerated Cross-linking.

12 Nov 2013

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.

11 Nov 2013

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

As of September 30, 2013, Delmar Pharmaceuticals has cash and equivalents of approximately $5.2 million and its working capital balance is in line with its expectations.

11 Nov 2013

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

IVIG is a hugely successful biological with FDA approval for treating idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barré syndrome, Graves ophthalmopathy and numerous polyneuropathies.

11 Nov 2013

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever.

11 Nov 2013

Mylan Pharmaceuticals launches Rabeprazole Sodium Delayed-release Tablets

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Rabeprazole Sodium Delayed-release Tablets, 20 mg.

11 Nov 2013

Patrys initiates IST of PAT-SM6 in combination with carfilzomib in multiple myeloma patients

Patrys Limited, a clinical stage biotechnology company has today announced that it is initiating an investigator-sponsored trial evaluating the effectiveness of Patrys’ lead anti-cancer drug PAT-SM6 in combination with carfilzomib, in patients with relapsed and refractory multiple myeloma.

11 Nov 2013

Chindex International third quarter 2013 revenue increases 16% to $43.1 million

Chindex International, Inc., an American healthcare company providing healthcare services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics, today announced financial results for the third quarter of 2013 ended September 30, 2013.

11 Nov 2013

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.

11 Nov 2013

ChinaSoft inks agreement with CITIC 21CN on Pharmaceutical Information Sharing Program

ChinaSoft International Limited, announced that it has signed a strategic agreement with CITIC 21CN Company Limited on the Pharmaceutical Information Sharing Program.

11 Nov 2013

Scientists study effect of diet complexity, estrogen hormone receptors on intestinal microbiota

Texas A&M University and University of North Carolina School of Medicine scientists have completed a study on the effect of diet complexity and estrogen hormone receptors on intestinal microbiota.

11 Nov 2013

Genovate, ScinoPharm to jointly develop new-generation oral Hepatitis B drug Livepro

Genovate Biotechnology Co. Ltd. and ScinoPharm Taiwan Ltd. announced today that they have jointly developed the highly potent oral generic drug Livepro (Entecavir), representing a new generation of drugs for the treatment of Hepatitis B. It is expected to be commercially available by the end of the year in Taiwan, accounting for more than NT$2 billion (US$70 million) worth of market opportunity.

11 Nov 2013

First generic versions of Aciphex delayed-release tablets get FDA approval for GERD treatment

The U.S. Food and Drug Administration today approved the first generic versions of Aciphex (rabeprazole sodium) delayed-release tablets, used to treat gastroesophageal reflux disease in adults and adolescents (ages 12 and up).

10 Nov 2013

Aptiom receives FDA approval to treat seizures associated with epilepsy

The U.S. Food and Drug Administration today approved Aptiom (eslicarbazepine acetate) as an add-on medication to treat seizures associated with epilepsy.

10 Nov 2013

Drug formulation services for highly potent active pharmaceutical ingredients provided by Evonik

Evonik Industries has broadened its capabilities in finished drug product formulation and clinical supply manufacturing and can now handle drug products containing highly potent active pharmaceutical ingredients (HPAPIs) in Darmstadt, Germany, and Birmingham, Alabama/USA. Investments in high containment facilities and upgrades in the laboratory and GMP areas in Birmingham enable Evonik to handle HPAPIs with occupational exposure limits (OEL) as low as 0.1μg/m3 and in Darmstadt as low as 1 μg/m3. Starting 2014, OEL as low as 0.1μg/m3 will also be possible in Darmstadt.

8 Nov 2013

New Torquers announced by Qosina

Qosina is pleased to announce the addition of three new Torquers, #97344 for use with guide wires 0.008 inch - 0.018 inch (0.20 mm - 0.46 mm, 0.6 FR - 1.4 FR) and #97345 or #97346 which fit 0.014 inch - 0.038 inch (0.36 mm - 0.96 mm, 1.1 FR - 3 FR). Torquer #97346 has a narrow profile design which is smaller and lighter than the other two.

8 Nov 2013

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

BioCryst Pharmaceuticals, Inc. today announced that it has dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in patients with hereditary angioedema.

8 Nov 2013

Pharmaceuticals News and Research

Orexigen Therapeutics reports net loss of $18.6 million in Q3 2013

Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Avedro initiates US clinical trials for Lasik with cross-linking and pulsed accelerated cross-linking

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

Mylan Pharmaceuticals launches Rabeprazole Sodium Delayed-release Tablets

Patrys initiates IST of PAT-SM6 in combination with carfilzomib in multiple myeloma patients

Chindex International third quarter 2013 revenue increases 16% to $43.1 million

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

ChinaSoft inks agreement with CITIC 21CN on Pharmaceutical Information Sharing Program

Scientists study effect of diet complexity, estrogen hormone receptors on intestinal microbiota

Genovate, ScinoPharm to jointly develop new-generation oral Hepatitis B drug Livepro

First generic versions of Aciphex delayed-release tablets get FDA approval for GERD treatment

Aptiom receives FDA approval to treat seizures associated with epilepsy

Drug formulation services for highly potent active pharmaceutical ingredients provided by Evonik

New Torquers announced by Qosina

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence